- Home
- JNJ
JNJ
Johnson & Johnson
as 04-23-2025 4:00pm EST
| Founded: | 1886 | Country: | United States |
| Employees: | N/A | City: | NEW BRUNSWICK |
| Market Cap: | N/A | IPO Year: | 1944 |
| Target Price: | $170.38 | AVG Volume (30 days): | 11.4M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 8.98 | EPS Growth: | -41.22 |
| 52 Week Low/High: | $140.68 - $169.99 | Next Earning Date: | 04-15-2025 |
| Revenue: | $89,331,000,000 | Revenue Growth: | 4.30% |
| Revenue Growth (this year): | 3.22% | Revenue Growth (next year): | 4.91% |
Stock Insider Trading Activity of Johnson & Johnson (JNJ)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Decker Robert J | JNJ | VP Corporate Controller | Feb 25 '25 | Sell | $165.88 | 6,999 | $1,160,994.12 | 21,001 | |
| Schmid Timothy | JNJ | EVP, WW Chair, MedTech | Feb 13 '25 | Sell | $156.15 | 403 | $62,928.45 | 15,098 | |
| Wolk Joseph J | JNJ | Exec VP, CFO | Feb 7 '25 | Sell | $153.89 | 13,015 | $2,002,878.35 | 0 |
Latest Johnson & Johnson News
JNJ Breaking Stock News: Dive into JNJ Ticker-Specific Updates for Smart Investing
StockStory
19 hours ago
JNJ Q1 Earnings: Pipeline Progress and MedTech Execution Drive Guidance Above Expectations
Benzinga
20 hours ago
Why Johnson & Johnson, Chevron, And Flowers Foods Are Winners For Passive Income
Simply Wall St.
a day ago
Johnson & Johnson (NYSE:JNJ) Showcases Paradigm-Shifting Bladder Cancer Trials at AUA 2025
Simply Wall St.
a day ago
Johnson & Johnson's (NYSE:JNJ) Dividend Will Be Increased To $1.30
StockStory
2 days ago
Johnson & Johnson (JNJ): Buy, Sell, or Hold Post Q1 Earnings?
MT Newswires
2 days ago
Johnson & Johnson to Present Latest Trial Data for TAR-200 to Treat Bladder Cancer
Insider Monkey
2 days ago
Is Johnson & Johnson (JNJ) the Best American Dividend Stock to Buy According to Analysts?
PR Newswire
2 days ago
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
Compare JNJ vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "JNJ Johnson & Johnson - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.